An experimental gut procedure helped a small group of patients maintain up to 80% of weight loss after stopping tirzepatide. A larger trial involving more than 300 people is underway.
Multiple research teams have developed innovative diabetes treatments including implantable insulin-producing cell devices, an oral insulin delivery platform using peptides, and a biological implant that functions as an autonomous artificial pancreas. These approaches have shown promising results in animal studies, with some devices maintaining glucose control for 90 days or more without immune suppression. The technologies represent potential alternatives to daily insulin injections for millions of diabetes patients worldwide.
Eli Lilly's oral GLP-1 drug orforglipron showed superior blood sugar control and weight loss compared to oral semaglutide in a year-long trial of over 1,500 patients with type 2 diabetes.
New research reveals red blood cells absorb large amounts of glucose in low-oxygen conditions, explaining why high-altitude populations have lower diabetes rates. A drug mimicking this effect completely reversed high blood sugar in diabetic mice.
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
Researchers discovered that red blood cells act as "glucose sponges" in low-oxygen conditions, dramatically lowering blood sugar levels. A new drug called HypoxyStat completely reversed high blood sugar in diabetic mice, working better than existing medications.
Scientists at Gladstone Institutes have discovered why living at high altitude reduces diabetes risk: red blood cells absorb large amounts of glucose in low oxygen environments. A drug mimicking this effect reversed diabetes in mice.
Semaglutide and other GLP-1 receptor agonists demonstrate substantial weight loss effectiveness through appetite regulation and blood sugar control, with clinical studies showing average reductions of 14.9% to 20.9% body weight.
Scientists in China report reversing Type 2 diabetes in a patient using stem cell therapy, while a separate study finds metformin may help women with diabetes live past 90. Both findings require larger trials.
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
